Literature DB >> 28373572

Bidirectional KCNQ1:β-catenin interaction drives colorectal cancer cell differentiation.

Raphael Rapetti-Mauss1,2, Viviana Bustos1, Warren Thomas1, Jean McBryan1, Harry Harvey1, Natalia Lajczak1, Stephen F Madden1, Bernard Pellissier2, Franck Borgese2, Olivier Soriani2, Brian J Harvey3.   

Abstract

The K+ channel KCNQ1 has been proposed as a tumor suppressor in colorectal cancer (CRC). We investigated the molecular mechanisms regulating KCNQ1:β-catenin bidirectional interactions and their effects on CRC differentiation, proliferation, and invasion. Molecular and pharmacologic approaches were used to determine the influence of KCNQ1 expression on the Wnt/β-catenin signaling and epithelial-to-mesenchymal transition (EMT) in human CRC cell lines of varying stages of differentiation. The expression of KCNQ1 was lost with increasing mesenchymal phenotype in poorly differentiated CRC cell lines as a consequence of repression of the KCNQ1 promoter by β-catenin:T-cell factor (TCF)-4. In well-differentiated epithelial CRC cell lines, KCNQ1 was localized to the plasma membrane in a complex with β-catenin and E-cadherin. The colocalization of KCNQ1 with adherens junction proteins was lost with increasing EMT phenotype. ShRNA knock-down of KCNQ1 caused a relocalization of β-catenin from the plasma membrane and a loss of epithelial phenotype in CRC spheroids. Overexpression of KCNQ1 trapped β-catenin at the plasma membrane, induced a patent lumen in CRC spheroids, and slowed CRC cell invasion. The KCNQ1 ion channel inhibitor chromanol 293B caused membrane depolarization, redistribution of β-catenin into the cytosol, and a reduced transepithelial electrical resistance, and stimulated CRC cell proliferation. Analysis of human primary CRC tumor patient databases showed a positive correlation between KCNQ1:KCNE3 channel complex expression and disease-free survival. We conclude that the KCNQ1 ion channel is a target gene and regulator of the Wnt/β-catenin pathway, and its repression leads to CRC cell proliferation, EMT, and tumorigenesis.

Entities:  

Keywords:  KCNQ1; adherens junctions; colon cancer; epithelial–mesenchymal transition; β-catenin

Mesh:

Substances:

Year:  2017        PMID: 28373572      PMCID: PMC5402468          DOI: 10.1073/pnas.1702913114

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  33 in total

Review 1.  The roles of K(+) channels in cancer.

Authors:  Luis A Pardo; Walter Stühmer
Journal:  Nat Rev Cancer       Date:  2013-12-12       Impact factor: 60.716

2.  Constitutive transcriptional activation by a beta-catenin-Tcf complex in APC-/- colon carcinoma.

Authors:  V Korinek; N Barker; P J Morin; D van Wichen; R de Weger; K W Kinzler; B Vogelstein; H Clevers
Journal:  Science       Date:  1997-03-21       Impact factor: 47.728

3.  Phosphorylation of beta-catenin by cyclic AMP-dependent protein kinase stabilizes beta-catenin through inhibition of its ubiquitination.

Authors:  Shin-ichiro Hino; Chie Tanji; Keiichi I Nakayama; Akira Kikuchi
Journal:  Mol Cell Biol       Date:  2005-10       Impact factor: 4.272

4.  Loss of imprinting of long QT intronic transcript 1 in colorectal cancer.

Authors:  K Tanaka; G Shiota; M Meguro; K Mitsuya; M Oshimura; H Kawasaki
Journal:  Oncology       Date:  2001       Impact factor: 2.935

5.  Oestrogen promotes KCNQ1 potassium channel endocytosis and postendocytic trafficking in colonic epithelium.

Authors:  Raphael Rapetti-Mauss; Fiona O'Mahony; Francisco V Sepulveda; Valerie Urbach; Brian J Harvey
Journal:  J Physiol       Date:  2013-03-25       Impact factor: 5.182

6.  Expression of voltage-gated potassium channels in human and mouse colonic carcinoma.

Authors:  Jiraporn Ousingsawat; Melanie Spitzner; Supaporn Puntheeranurak; Luigi Terracciano; Luigi Tornillo; Lukas Bubendorf; Karl Kunzelmann; Rainer Schreiber
Journal:  Clin Cancer Res       Date:  2007-02-01       Impact factor: 12.531

7.  A homolog of the armadillo protein in Drosophila (plakoglobin) associated with E-cadherin.

Authors:  P D McCrea; C W Turck; B Gumbiner
Journal:  Science       Date:  1991-11-29       Impact factor: 47.728

8.  Transcriptional and post-transcriptional mechanisms for oncogenic overexpression of ether à go-go K+ channel.

Authors:  Huixian Lin; Zhe Li; Chang Chen; Xiaobin Luo; Jiening Xiao; Deli Dong; Yanjie Lu; Baofeng Yang; Zhiguo Wang
Journal:  PLoS One       Date:  2011-05-31       Impact factor: 3.240

9.  Regulation of functional KCNQ1OT1 lncRNA by β-catenin.

Authors:  Naohiro Sunamura; Takahito Ohira; Miki Kataoka; Daigo Inaoka; Hideyuki Tanabe; Yuji Nakayama; Mitsuo Oshimura; Hiroyuki Kugoh
Journal:  Sci Rep       Date:  2016-02-12       Impact factor: 4.379

10.  Loss of KCNQ1 expression in stage II and stage III colon cancer is a strong prognostic factor for disease recurrence.

Authors:  Sjoerd H den Uil; Veerle M H Coupé; Janneke F Linnekamp; Evert van den Broek; Jeroen A C M Goos; Pien M Delis-van Diemen; Eric J Th Belt; Nicole C T van Grieken; Patricia M Scott; Louis Vermeulen; Jan Paul Medema; Herman Bril; Hein B A C Stockmann; Robert T Cormier; Gerrit A Meijer; Remond J A Fijneman
Journal:  Br J Cancer       Date:  2016-11-17       Impact factor: 7.640

View more
  28 in total

1.  Drug Repurposing: The Anthelmintics Niclosamide and Nitazoxanide Are Potent TMEM16A Antagonists That Fully Bronchodilate Airways.

Authors:  Kent Miner; Katja Labitzke; Benxian Liu; Paul Wang; Kathryn Henckels; Kevin Gaida; Robin Elliott; Jian Jeffrey Chen; Longbin Liu; Anh Leith; Esther Trueblood; Kelly Hensley; Xing-Zhong Xia; Oliver Homann; Brian Bennett; Mike Fiorino; John Whoriskey; Gang Yu; Sabine Escobar; Min Wong; Teresa L Born; Alison Budelsky; Mike Comeau; Dirk Smith; Jonathan Phillips; James A Johnston; Joseph G McGivern; Kerstin Weikl; David Powers; Karl Kunzelmann; Deanna Mohn; Andreas Hochheimer; John K Sullivan
Journal:  Front Pharmacol       Date:  2019-02-14       Impact factor: 5.810

2.  Potassium and Calcium Channel Complexes as Novel Targets for Cancer Research.

Authors:  Marie Potier-Cartereau; William Raoul; Gunther Weber; Karine Mahéo; Raphael Rapetti-Mauss; Maxime Gueguinou; Paul Buscaglia; Caroline Goupille; Nelig Le Goux; Souleymane Abdoul-Azize; Thierry Lecomte; Gaëlle Fromont; Aurélie Chantome; Olivier Mignen; Olivier Soriani; Christophe Vandier
Journal:  Rev Physiol Biochem Pharmacol       Date:  2022       Impact factor: 5.545

3.  Physiological Functions, Biophysical Properties, and Regulation of KCNQ1 (KV7.1) Potassium Channels.

Authors:  Michael C Sanguinetti; Guiscard Seebohm
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

4.  Inhibition of ClC-5 suppresses proliferation and induces apoptosis in cholangiocarcinoma cells through the Wnt/β-catenin signaling pathway.

Authors:  Zhe Shi; Liyuan Zhou; Yan Zhou; Xiaoyan Jia; Xiangjun Yu; Xiaohong An; Yanzhen Han
Journal:  BMB Rep       Date:  2022-06       Impact factor: 5.041

Review 5.  How Dysregulated Ion Channels and Transporters Take a Hand in Esophageal, Liver, and Colorectal Cancer.

Authors:  Christian Stock
Journal:  Rev Physiol Biochem Pharmacol       Date:  2021       Impact factor: 5.545

Review 6.  From Channels to Canonical Wnt Signaling: A Pathological Perspective.

Authors:  Silvia Muccioli; Valentina Brillo; Leonardo Chieregato; Luigi Leanza; Vanessa Checchetto; Roberto Costa
Journal:  Int J Mol Sci       Date:  2021-04-28       Impact factor: 5.923

7.  Tumor Suppressor Gene XEDAR Promotes Differentiation and Suppresses Proliferation and Migration of Gastric Cancer Cells Through Upregulating the RELA/LXRα Axis and Deactivating the Wnt/β-Catenin Pathway.

Authors:  Xinwu Zhang; Di Zhang; Xiaoli Sun; Shunle Li; Yun Sun; Hongjun Zhai
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064

8.  GPER mediates differential effects of estrogen on colon cancer cell proliferation and migration under normoxic and hypoxic conditions.

Authors:  Viviana Bustos; Áine M Nolan; Anke Nijhuis; Harry Harvey; Alexandra Parker; Richard Poulsom; Jean McBryan; Warren Thomas; Andrew Silver; Brian J Harvey
Journal:  Oncotarget       Date:  2017-09-06

9.  Identifying Novel Susceptibility Genes for Colorectal Cancer Risk From a Transcriptome-Wide Association Study of 125,478 Subjects.

Authors:  Xingyi Guo; Weiqiang Lin; Wanqing Wen; Jeroen Huyghe; Stephanie Bien; Qiuyin Cai; Tabitha Harrison; Zhishan Chen; Conghui Qu; Jiandong Bao; Jirong Long; Yuan Yuan; Fangqin Wang; Mengqiu Bai; Goncalo R Abecasis; Demetrius Albanes; Sonja I Berndt; Stéphane Bézieau; D Timothy Bishop; Hermann Brenner; Stephan Buch; Andrea Burnett-Hartman; Peter T Campbell; Sergi Castellví-Bel; Andrew T Chan; Jenny Chang-Claude; Stephen J Chanock; Sang Hee Cho; David V Conti; Albert de la Chapelle; Edith J M Feskens; Steven J Gallinger; Graham G Giles; Phyllis J Goodman; Andrea Gsur; Mark Guinter; Marc J Gunter; Jochen Hampe; Heather Hampel; Richard B Hayes; Michael Hoffmeister; Ellen Kampman; Hyun Min Kang; Temitope O Keku; Hyeong Rok Kim; Loic Le Marchand; Soo Chin Lee; Christopher I Li; Li Li; Annika Lindblom; Noralane Lindor; Roger L Milne; Victor Moreno; Neil Murphy; Polly A Newcomb; Deborah A Nickerson; Kenneth Offit; Rachel Pearlman; Paul D P Pharoah; Elizabeth A Platz; John D Potter; Gad Rennert; Lori C Sakoda; Clemens Schafmayer; Stephanie L Schmit; Robert E Schoen; Fredrick R Schumacher; Martha L Slattery; Yu-Ru Su; Catherine M Tangen; Cornelia M Ulrich; Franzel J B van Duijnhoven; Bethany Van Guelpen; Kala Visvanathan; Pavel Vodicka; Ludmila Vodickova; Veronika Vymetalkova; Xiaoliang Wang; Emily White; Alicja Wolk; Michael O Woods; Graham Casey; Li Hsu; Mark A Jenkins; Stephen B Gruber; Ulrike Peters; Wei Zheng
Journal:  Gastroenterology       Date:  2020-10-12       Impact factor: 33.883

10.  The Role of KCNQ1 Mutations and Maternal Beta Blocker Use During Pregnancy in the Growth of Children With Long QT Syndrome.

Authors:  Heta Huttunen; Matti Hero; Mitja Lääperi; Johanna Känsäkoski; Heikki Swan; Joel A Hirsch; Päivi J Miettinen; Taneli Raivio
Journal:  Front Endocrinol (Lausanne)       Date:  2018-04-24       Impact factor: 5.555

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.